Novo Nordisk
NVO
707 hedge funds and large institutions have $8.87B invested in Novo Nordisk in 2021 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 259 increasing their positions, 210 reducing their positions, and 56 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 259 | Existing positions reduced: 210
21% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 56
1% more funds holding
Funds holding: 702 → 707 (+5)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.5% less ownership
Funds ownership: 15.06% → 14.56% (-0.5%)
7% less capital invested
Capital invested by funds: $9.54B → $8.87B (-$665M)
21% less call options, than puts
Call options by funds: $21.8M | Put options by funds: $27.5M
Top Buyers
| 1 |
BlackRock
New York
|
+$132M |
| 2 |
FP
Financial Perspectives
Minneapolis,
Minnesota
|
+$40M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$30.3M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$25.2M |
| 5 |
Millennium Management
New York
|
+$25M |
Top Sellers
NVO Hedge Fund Activity: Q1 2021 in Review
707 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2021, worth a combined $8.87B — down 7% from $9.54B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new NVO positions and 56 closed out — a net gain of 12 holders — while 259 added to existing stakes and 210 trimmed.
The largest buyer was BlackRock, adding an estimated $132M. The largest seller was Renaissance Technologies, cutting an estimated $142M.
- 707 institutional investors held Novo Nordisk (NVO) as of Q1 2021, up from 702 in Q4 2020.
- Funds reported $8.87B of Novo Nordisk stock for Q1 2021, down 7% quarter-over-quarter.
- 68 funds opened new Novo Nordisk positions in Q1 2021 and 56 closed out, a net change of +12 holders.
- The largest Novo Nordisk buyer in Q1 2021 was BlackRock, an estimated $132M added.
- The largest Novo Nordisk seller in Q1 2021 was Renaissance Technologies, an estimated $142M sold.
Based on aggregated 13F filings for Q1 2021.